Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 21856226

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2011 Sep
First author
Kantarjian HM

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2011 Oct;12(11):989
    note
    Source null
    related pmid
    Source null
    relationship
    Erratum in
    url
    Source null
  2. citation
    Lancet Oncol. 2011 Sep;12(9):826-7. doi: 10.1016/S1470-2045(11)70228-5.
    note
    Source null
    related pmid
    21856227
    relationship
    Comment in

Authors and identifiers

  1. name
    Kantarjian HM
    type
    Author
  2. name
    Hochhaus A
    type
    Author
  3. name
    Saglio G
    type
    Author
  4. name
    De Souza C
    type
    Author
  5. name
    Flinn IW
    type
    Author
  6. name
    Stenke L
    type
    Author
  7. name
    Goh YT
    type
    Author
  8. name
    Rosti G
    type
    Author
  9. name
    Nakamae H
    type
    Author
  10. name
    Gallagher NJ
    type
    Author
  11. name
    Hoenekopp A
    type
    Author
  12. name
    Blakesley RE
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Kantarjian HM
    type
    Author
  2. name
    Hochhaus A
    type
    Author
  3. name
    Saglio G
    type
    Author
  4. name
    De Souza C
    type
    Author
  5. name
    Flinn IW
    type
    Author
  6. name
    Stenke L
    type
    Author
  7. name
    Goh YT
    type
    Author
  8. name
    Rosti G
    type
    Author
  9. name
    Nakamae H
    type
    Author
  10. name
    Gallagher NJ
    type
    Author
  11. name
    Hoenekopp A
    type
    Author
  12. name
    Blakesley RE
    type
    Author
bibliography ids
  1. nci-bib-34dbc487d14c0668892ec314
book metadata
content sha256
98899086f3178ef52248225c4dd810d277940425e0aadd900309f44552744579
document type
citation
dois
  1. 10.1016/S1470-2045(11)70201-7
electronic publication date
display
2011 Aug 17
precision
day
year
2011
evidence scope
bibliographic_metadata_only
id
pubmed:21856226
immutable id
pubmed:21856226@98899086f3178ef52248225c4dd810d277940425e0aadd900309f44552744579
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
9
name
The Lancet. Oncology
nlm unique id
100957246
pages
841-51
volume
12
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2011 Oct;12(11):989
    note
    Source null
    related pmid
    Source null
    relationship
    Erratum in
    url
    Source null
  2. citation
    Lancet Oncol. 2011 Sep;12(9):826-7. doi: 10.1016/S1470-2045(11)70228-5.
    note
    Source null
    related pmid
    21856227
    relationship
    Comment in
outcomes validated
false
pmid
21856226
provenance
batch id
2529ef2eca926738ab13
provider
NCBI PubMed ESummary
record sha256
dda4c21eabb01231ed28499ecd8841ac997b9a23ae6721b714df9622c21b5ea6
response sha256
9204e3dd8d67df5a6773613a8059d8d42d9842ee24eecc9b0f39a62f636c99b6
retrieved at
2026-09-09T23:46:42.856296+00:00
publication date
display
2011 Sep
precision
month
year
2011
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/21856226/
title
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.

Preserved source evidence · Not medical advice